TICINO: MILAN’S SWISS SPOTLIGHT ON GENEVA’S FUNDING BIOTECH ‘INDUSTRY 4.0’ - SUBURB? HEALTH VALLEY PAGE 38 SPOTLIGHT ON PROCESS PAGE 49 PAGE 12 AUTOMATION PAGE 14 A KALEIDOSCOPE OF EXCELLENCE page 21 SWITZERLAND JUNE 2017 Acknowledgements Pharmaboardroom would like to thank: Raymond Cron, CEO, Switzerland Innovation Nic Alexakis, CEO, Swiss Biotech Association Urs Gasche, president, FASMED Gilles Pluntz, chairman of Group Operating Committee & SVP Europe- Canada, Ferring Giorgio Calderari, chairman, Farma Industria Ticino (FIT) Riccardo Braglia, group vice chairman & CEO, Helsinn As well as all of the companies we have met for their support, assistance and enthusiasm. 2 Healthcare & Life Sciences Review: Switzerland www.pharmaboardroom.com HEALTHCARE & LIFE SCIENCES REVIEW SWITZERLAND Geneva: Switzerland’s Budding Health Valley Article 12 CONTENTS — June 2017 2 ACKNOWLEDGEMENTS 5 PREFACE 6 SNAPSHOT IN FIGURES A Kaleoidoscope 10 INVESTING IN WESTERN SWITZERLAND of Excellence INTERVIEW Thomas Bohn, Greater Geneva Bern area (GGBa) Cover story 21 12 GEO-SPACIAL FOCUS FEATURE West Switzertland 14 PROCESS AUTOMATION FEATURE Next-Gen Pharma Processes 16 HEALTH INSURANCE INTERVIEW Daniel Schmutz, Helsana 19 REGIONAL HEADQUARTERS INTERVIEW Shigeo Taniuchi, Santen 21 A KALEIDOSCOPE OF EXCELLENCE COVER STORY 22 World-Class Service Providers 26 The Essence of Swissness 31 Market Quirkness 34 Digital Prowess 38 Swiss Biotech’s Funding Quandary 41 Mid-Caps and Minnows: at the Vanguard of Creativity Interview with Gilles Pluntz, SVP Europe- 46 Cluster of Clusters Canada at Ferring 47 Decision Points Interview 61 49 Ticino: Milan’s Swiss Suburb? 52 Ticino: Bastion of Pharma Services The Healhcare & Life Sciences Review was produced 55 ‘Sonderfall Schweiz’ by PharmaBoardroom. 57 DIABETES TREATMENT INTERVIEW Project Publisher: Diana Viola Mads Stoustrup, Novo Nordisk Senior Editor: Louis Haynes Editor: Patrick Burton 58 MEDICAL DEVICES FEATURE Project Directors: Crystelle Coury, Valerie Baia Swiss Excellence Contibutors: Jannes Peemöller, Alexander Ackerman, Julija Lukaityte 61 REPRODUCTIVE HEALTH INTERVIEW Graphic Designer: Miriam León, Laura Breitfeld Gilles Pluntz, Ferring For exclusive interviews and more info, please log onto 62 HOMEOPATHIC REMEDIES FEATURE www.pharmaboardroom.com or write to [email protected]. Urs Lehmann, Similasan Copyright: All rights reserved. No part of this publication maybe reproduced in any form or by any means, whether electronic, mechanical or otherwise including photo- 64 CDMO SRATEGY INTERVIEW Juerg Burger, CordenPharma copying, recording or any information storage or retrieval system without prior written consent of Focus Reports. While every attempt is made to ensure the accuracy of the 66 ONCOLOGY INTERVIEW information contained in this report, neither Focus Reports nor the authors accept any liabilities forerrors and omissions. Opinions expressed in this report are not necessarily Riccardo Braglia, Helsinn those of the authors. www.pharmaboardroom.com Healthcare & Life Sciences Review: Switzerland 3 STAY IN TOUCH: @pharmaboardroom www.pharmaboardroom.com JOIN THE CONVERSATION Switzerland Additional full-feature interviews from our Switzerland 2017 Report can be accessed on PharmaBoardroom, the premier website for C-Level executives, consultants and state actors in the pharmaceuticals and life sciences sector, alongside hundreds of exclusive interviews featuring the main movers and shakers of the industry, free country reports and sector insights supplemented by the latest news from global markets. AMPLIFIED CONTENT IN BRIEF HENK MEERTENS @pharmaboardroom Vice President, Benelux, Central Raymond Cron of the #Switzerland #Innovation Europe, Greece & Israel, Medtronic Foundation @swissinnova discusses the new Switzerland Innovation Park Read the inteview SUSANNE HOEPPNER General Manager, Astellas @pharmaboardroom Switzerland Jurgi Camblong of @SophiaGenetics #Switzerland on turning data driven medicine into a reality LUCAS BAUMANN CEO, Rausch, Switzerland Read the interview @pharmaboardroom Bridget-Anne Kirwan of SOCAR Research talks BERNARD CLOËTTA, DR. IUR. #clinicaltrials in #Switzerland Director General, Swiss Cosmetics & Detergent Association (SKW) Read the interview @pharmaboardroom ROEL VAN DOREN Michele Genovesi of SFI talks #nutraceuticals President Europe, Emerson and #naturalsolutions in #Switzerland Automation Solutions, Switzerland Read the interview PREFACE Preface As part of our series on Switzerland, this report in Switzerland’ brand abroad, Swiss companies’ delves into the specificities of Swiss pharma- cutting-edge digital prowess, the Swiss biotechs ceuticals, biotech, and healthcare, based on turning to the US for investment, mid-caps and in-depth interviews conducted with leaders and minnows at the vanguard of creativity, and the pioneers across the value chain, from govern- variety of regional clusters outside of the tradi- ment representatives, global affiliate heads, and tional healthcare heartland of Basel, home to founders of innovative local SMEs. Novartis and Roche. In particular, the report In spite of high operating costs and a some- examines the canton of Ticino, an oft-over- times-byzantine regulatory environment, major looked Italian-speaking region in the south of MNCs are flocking to establish regional head- Switzerland which is rapidly turning a tradition quarters in a country frequently ranked the of research and academic excellence into com- most innovative in the world. Complementary mercial innovation locally. thriving ecosystems of biotech startups, con- For those wishing to scratch beneath the sur- tract research and manufacturing organizations, face and discover why Switzerland has achieved as well as a whole host of niche service providers such success in healthcare and the life sciences have also sprung up across Switzerland, many of and how the Swiss are poised to achieve even which are featured inside. Key themes featured more in the coming years, this report is essen- in this report include the resonance of the ‘Made tial reading. SNAPSHOT IN FIGURES Pharmaceutical Market PHARMACEUTICAL MARKET IN TOP 5 COMPANIES SWITZERLAND BY VALUE ACCORDING TO THE NUMBER OF EMPLOYEES IN MARKET VALUE 2015: USD 5.5 BILLION SWITZERLAND IN 2013 (AT EX-FACTORY PRICES, 100%) 2.9 billion 1.3 billion #1 NOVARTIS 24.1% 1.2 billion #2 ROCHE 52% 22.7% 1.2% #3 JANSSEN 70.6 million #4 VIFOR PHARMA + Pharmacies Self-dispensing doctors Hospitals Drugstores #5 ACTELION Source: Interpharma with database IMS Health Switzerland, 2016. Source: Interpharma, 2014 SWISS EXPORTS BY INDUSTRY Source: Swiss Biotech Association, ‘Swiss Biotech Report 2017’ 250 Swiss Exports (billion CHF) 200 Chemicals and related products Chemicals and related products 150 100 Pharmaceuticals, Vitamins, Diagnostics Metals and machinery CHF 80.3 bn, 85.1% Other, CHF 3.0 bn, 3.2% Pigments, CHF 1.4 bn, 1.5% 50 Watches Essential oils, Flavour & Fragrances, Food and tobacco CHF 1.6 bn, 1.7% Plastics, Textiles and clothing CHF 1.8 bn, 1.9% Raw materials 0 Other products CHF 4.0 bn, 4.3% 2001 2006 2011 2016 Agrochemicals Technology Relevance CHF 2.2 bn, 2.3% 6 Healthcare & Life Sciences Review: Switzerland www.pharmaboardroom.com SNAPSHOT IN FIGURES R&D and Innovation R&D EXPENDITURE IN SWITZERLAND INVESTMENT IN R&D BY INDUSTRY AND ABROAD TOTAL EXPENDITURE ON R&D (2012): CHF 12,819 MILLION PRIVATE SECTOR ONLY: 2008; IN MILLIONS OF CHF AND % (USD 13,090 MILLION) 29.6% 39% 5% Pharma R&D 17.0% SWITZERLAND Other 11.979 15.7% 28% Machines/ Metal 28% 14.4% Mechanical electrical R&D engineering industries (MEM) 10.8% 67% Chemicals ICT R&D Pharmaceuticals 8.0% SUBSIDIARIES High Technology Instruments ABROAD Others 15.796 4.0% Chemistry 5% 0.5% Source: Federal Office for Statistics; 21% 7% Source: Deloitte (2013) Food Interpharma NUMBER OF ACTIVE PATENTS PER YEAR AND COUNTRY Source: Swiss Biotech Association, ‘Swiss Biotech Report 2017’ Number of active patients Invented in 80,000 China 70,000 USA 60,000 Japan South Korea 50,000 Germany 40,000 France United Kingdom 30,000 Canada 20,000 Russia 10,000 Netherlands Switzerland Reporting Australia 2011 2012 2013 2015 2016 2014 2010 year 2001 2007 2002 2003 2005 2008 2009 2006 2004 2000 Denmark www.pharmaboardroom.com Healthcare & Life Sciences Review: Switzerland 7 SNAPSHOT IN FIGURES Biotech NUMBER OF BIOTECH COMPANIES IN SWITZERLAND Developers Source: Swiss Biotech Association, Suppliers ‘Swiss Biotech Report 2017’, EY 240 220 200 180 160 140 120 100 80 60 Source: Swiss Biotech 40 20 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 SWISS PHARMA AND BIOTECH HOTSPOTS Source: Swiss Biotech BioValley, one of the leading BASEL European Life Sciences regions Global headquarters of Novartis and Roche. in the world, bringing together 69 Biotech companies ZURICH including Zug three regions from France, 52 Biotech companies Germany and Switzerland LAUSANNE Lake Geneva region: 48 Biotech companies SWITZERLAND GENEVA Unofficial “world capital of LUGANO health” Home to UN, WHO and Red cross Ticino region: 26 Biotech companies INDICATIONS FOR SWISS BIOTECH PRODUCTS MARKET VALUE: CHF 929.1 MILLION (USD 948.4 MILLION) 23.2% % 31.4 Cancer Ophthalmology 10.0% Rheumatism Haematology 9.7% Multiple Sclerosis Vaccines 7.2% Other Growth Hormones 6.9% Diabetes 4.6% 4.2% Source: Interpharma; IMS Health 2.8% Switzerland (2016) 8 Healthcare & Life Sciences Review: Switzerland www.pharmaboardroom.com SNAPSHOT IN FIGURES Biotech NUMBER OF EMPLOYEES IN BIOTECH INDUSTRY Source: Swiss Biotech Association,